Scope of the Study
An Artificial heart is device that replace original heart and it perform like original heart. It can be consider as prosthetic device fixed into the body to substitute the organic mammalian heart. Person can live with artificial heart from a few weeks to more than one year. Risk associated with treatment for artificial heart implementation because it can lead to bleed and infection.
The market study is being classified by Type (Ventricular Assist Device (VAD) and Total Artificial Heart) and major geographies with country level break-up.
SynCardia Systems (United States), BiVACOR (United States), CARMAT (France), Abbott (United States), Cleveland Heart (United States), AbioMed (United States), Jarvik Heart (United States), Cirtec Medical Systems (United States), Thoratec Corporation (United States), Boston Scientific Corporation (United States) and Braile Biomedica (Brazil) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Colibri Heart Valve LLC (United States), Cryolife Inc. (United States), Edwards Lifesciences Corporation (United States), Heart Leaflet Technology (United States), Jenavalve Technology Inc.(Germany) and Leman Cardiovascular (Switzerland).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Artificial Heart market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Artificial Heart market by Type, Application and Region.
On the basis of geography, the market of Artificial Heart has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospitals will boost the Artificial Heart market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rising Mortality Ratio Due To Cardiovascular Diseases
- Unhealthy Lifestyle
- Undesirable Atmospheric Conditions
- Increasing Awareness about New Technological Innovations
- Government Initiation towards Providing Funds for Treatment of Heart Dieses
- Expensive Treatment
- Risk Associated With Transplant Procedure
- Strict Regulatory Approvals
- Increasing Healthcare Infrastructure in Emerging Nations
- Need of Skilled Cardiac Specialist
- Threat of Substitution by using Alternative Methods
On 1st August 2018, CARMAT the designer and developer of the world's most advanced total artificial heart project has announced successful transplant of a donor heart in the first international patient implanted with the CARMAT heart in October 2017. and On 29th May 2018, Boston Scientific Europe has launched the HeartLogic™ Heart Failure Diagnostic in Europe. It provides a diagnostic tool that enables proactive heart failure (HF) care.
Key Target AudienceArtificial heart Suppliers, Artificial heart Manufacturers, Research Laboratories, Medical Devices Industries, Medical Institutes, Government Research Centre and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase